The use of the same physiotherapists to administer both PNE and BME interventions in the EduCan trial raises concerns about potential bias, as no safeguards ensuring objectivity were detailed. Additionally, the reliance on subjective measures such as the Visual Analogue Scale (VAS) and Pain Disability Index (PDI) without clear validation for the oncological context may affect the reliability of the findings. Could the authors provide clarification on these critical points, particularly regarding steps taken to mitigate bias and the rationale for selecting these assessment tools?
